Glizamide M Tablet is an effective combination therapy for Type 2 Diabetes Mellitus (T2DM), containing Glibenclamide (5mg), Metformin Hydrochloride (500mg), and Pioglitazone Hydrochloride (15mg). This formulation is designed to provide comprehensive glycemic control by targeting different mechanisms responsible for elevated blood sugar levels. It is particularly beneficial for patients who require multi-drug therapy to achieve optimal glucose regulation.
-
Glibenclamide (Sulfonylurea Class): Works by stimulating the pancreas to release more insulin, effectively lowering blood sugar levels.
-
Metformin Hydrochloride (Biguanide Class): Reduces hepatic glucose production and enhances insulin sensitivity, allowing better glucose uptake by the body's cells.
-
Pioglitazone Hydrochloride (Thiazolidinedione Class): Improves insulin responsiveness, helping to lower insulin resistance and regulate glucose metabolism.
Glizamide M Tablet is particularly useful for patients who do not achieve adequate blood sugar control with single or dual therapy. It helps in reducing fasting and postprandial glucose levels, thereby preventing complications associated with diabetes, such as neuropathy, nephropathy, cardiovascular diseases, and retinal disorders.
This medication is most effective when combined with a healthy diet, regular physical activity, and lifestyle modifications. Patients with obesity-linked diabetes may find additional benefits, as Metformin assists in weight management, while Pioglitazone helps improve lipid metabolism.
Regular monitoring of blood sugar levels, kidney function, and liver enzymes is essential while using this medication. Patients with cardiovascular conditions, liver impairment, or a history of bladder cancer should use it with caution and only under medical supervision.